Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3 Recruiting

300 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2 Recruiting

202 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Phase 2 Recruiting

47 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04544969 2025-01-28

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Recruiting

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplastic Cells, Circulating

NCT06323239 2024-08-20

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2 Recruiting

148 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05979961 2024-08-06

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

454 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06019130 2024-05-16

NPC-Nivo

Phase 2 Recruiting

57 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

228 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03919552 2023-06-18

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Recruiting

482 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Phase 3 Recruiting

244 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05527470 2023-05-03

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Recruiting

440 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05717790 2023-02-08

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Phase NA Recruiting

288 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05674305 2023-01-10

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Phase 3 Recruiting

366 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04898374 2022-08-17

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Phase 3 Recruiting

120 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05352321 2022-07-01

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Phase NA Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04437329 2022-05-10

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Phase 3 Recruiting

352 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04136886 2019-10-23

IMRT

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

NPC-Nivo

GNT Induction Treatment in Locally Advanced NPC

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

IMRT